Click here to get full coverage on Piper Sandler Maintains Aquestive Therapeutics (AQST) Overweight Recommendation - Nasdaq

Piper Sandler Maintains Aquestive Therapeutics (AQST) Overweight Recommendation  Nasdaq

Piper Sandler Maintains Aquestive Therapeutics (AQST) Overweight Recommendation - Nasdaq

Click here to get full coverage on Aquestive Therapeutics, Inc. (NASDAQ:AQST) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.10 - Yahoo Finance

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.10  Yahoo Finance

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.10 - Yahoo Finance

Click here to get full coverage on Is Aquestive Therapeutics Stock Built to Withstand a Pullback? - Trefis

Is Aquestive Therapeutics Stock Built to Withstand a Pullback?  Trefis

Is Aquestive Therapeutics Stock Built to Withstand a Pullback? - Trefis

Click here to get full coverage on Aquestive Therapeutics Stock: A Measured Bet (NASDAQ:AQST) - Seeking Alpha

Aquestive Therapeutics Stock: A Measured Bet (NASDAQ:AQST)  Seeking Alpha

Aquestive Therapeutics Stock: A Measured Bet (NASDAQ:AQST) - Seeking Alpha

Click here to get full coverage on Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors - simplywall.st

Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors  simplywall.st

Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors - simplywall.st

Click here to get full coverage on AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA - Zacks Investment Research

AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA  Zacks Investment Research

AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA - Zacks Investment Research

Click here to get full coverage on Aquestive Therapeutics (NASDAQ: AQST) notes Jan 2026 PDUFA; reports $12.8M revenue - Stock Titan

Aquestive Therapeutics (NASDAQ: AQST) notes Jan 2026 PDUFA; reports $12.8M revenue  Stock Titan

Aquestive Therapeutics (NASDAQ: AQST) notes Jan 2026 PDUFA; reports $12.8M revenue - Stock Titan

Click here to get full coverage on Aquestive Therapeutics Inc (AQST) Q3 2025 Earnings Report Preview: What To Look For - Yahoo Finance

Aquestive Therapeutics Inc (AQST) Q3 2025 Earnings Report Preview: What To Look For  Yahoo Finance

Aquestive Therapeutics Inc (AQST) Q3 2025 Earnings Report Preview: What To Look For - Yahoo Finance

Click here to get full coverage on Retail investors who have a significant stake must be disappointed along with institutions after Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) market cap dropped by US$77m - simplywall.st

Retail investors who have a significant stake must be disappointed along with institutions after Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) market cap dropped by US$77m  simplywall.st

Retail investors who have a significant stake must be disappointed along with institutions after Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) market cap dropped by US$77m - simplywall.st

Click here to get full coverage on Aquestive (NASDAQ: AQST) appoints Matthew Davis CDO; Gary Slatko named interim CMO - Stock Titan

Aquestive (NASDAQ: AQST) appoints Matthew Davis CDO; Gary Slatko named interim CMO  Stock Titan

Aquestive (NASDAQ: AQST) appoints Matthew Davis CDO; Gary Slatko named interim CMO - Stock Titan

Click here to get full coverage on Here's What Key Metrics Tell Us About Aquestive Therapeutics (AQST) Q3 Earnings - Yahoo Finance

Here's What Key Metrics Tell Us About Aquestive Therapeutics (AQST) Q3 Earnings  Yahoo Finance

Here's What Key Metrics Tell Us About Aquestive Therapeutics (AQST) Q3 Earnings - Yahoo Finance

Click here to get full coverage on Aquestive Therapeutics (AQST) Soars 14.8%: Is Further Upside Left in the Stock? - Yahoo Finance

Aquestive Therapeutics (AQST) Soars 14.8%: Is Further Upside Left in the Stock?  Yahoo Finance

Aquestive Therapeutics (AQST) Soars 14.8%: Is Further Upside Left in the Stock? - Yahoo Finance

Click here to get full coverage on Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?  Yahoo Finance

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Click here to get full coverage on Aquestive Therapeutics Inc (AQST) Q2 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance

Aquestive Therapeutics Inc (AQST) Q2 2025: Everything You Need To Know Ahead Of Earnings  Yahoo Finance

Aquestive Therapeutics Inc (AQST) Q2 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance

Click here to get full coverage on Aquestive Therapeutics (AQST) Surges 7.9%: Is This an Indication of Further Gains? - Yahoo Finance

Aquestive Therapeutics (AQST) Surges 7.9%: Is This an Indication of Further Gains?  Yahoo Finance

Aquestive Therapeutics (AQST) Surges 7.9%: Is This an Indication of Further Gains? - Yahoo Finance

Click here to get full coverage on Aquestive Therapeutics, Inc. (AQST): Analysts See 245% Upside Potential - Yahoo Finance

Aquestive Therapeutics, Inc. (AQST): Analysts See 245% Upside Potential  Yahoo Finance

Aquestive Therapeutics, Inc. (AQST): Analysts See 245% Upside Potential - Yahoo Finance

Click here to get full coverage on Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates  Yahoo Finance

Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Institutional investors are Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) biggest bettors and were rewarded after last week's US$47m market cap gain - Yahoo Finance

Institutional investors are Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) biggest bettors and were rewarded after last week's US$47m market cap gain  Yahoo Finance

Institutional investors are Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) biggest bettors and were rewarded after last week's US$47m market cap gain - Yahoo Finance

Click here to get full coverage on H.C. Wainwright Reaffirms Buy on Aquestive Therapeutics, Inc. (AQST) After FDA Approval - Yahoo Finance

H.C. Wainwright Reaffirms Buy on Aquestive Therapeutics, Inc. (AQST) After FDA Approval  Yahoo Finance

H.C. Wainwright Reaffirms Buy on Aquestive Therapeutics, Inc. (AQST) After FDA Approval - Yahoo Finance

Click here to get full coverage on Aquestive Therapeutics (AQST) Is Up 6.8% After FDA Clears Path for Needle-Free Epinephrine Film Approval - simplywall.st

Aquestive Therapeutics (AQST) Is Up 6.8% After FDA Clears Path for Needle-Free Epinephrine Film Approval  simplywall.st

Aquestive Therapeutics (AQST) Is Up 6.8% After FDA Clears Path for Needle-Free Epinephrine Film Approval - simplywall.st

Click here to get full coverage on Earnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their Forecasts - simplywall.st

Earnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their Forecasts  simplywall.st

Earnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their Forecasts - simplywall.st

Click here to get full coverage on Aquestive Therapeutics (AQST) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Aquestive Therapeutics (AQST) Reports Q3 Loss, Lags Revenue Estimates  Yahoo Finance

Aquestive Therapeutics (AQST) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Jim Cramer on Aquestive Therapeutics: “I think it’s Worth Taking a Chance On” - Yahoo Finance

Jim Cramer on Aquestive Therapeutics: “I think it’s Worth Taking a Chance On”  Yahoo Finance

Jim Cramer on Aquestive Therapeutics: “I think it’s Worth Taking a Chance On” - Yahoo Finance

Click here to get full coverage on How Recent Regulatory Wins Are Shaping the Narrative for Aquestive Therapeutics - Yahoo Finance

How Recent Regulatory Wins Are Shaping the Narrative for Aquestive Therapeutics  Yahoo Finance

How Recent Regulatory Wins Are Shaping the Narrative for Aquestive Therapeutics - Yahoo Finance

Click here to get full coverage on Aquestive Therapeutics (AQST) CEO Barber sells $2400 in stock - Investing.com

Aquestive Therapeutics (AQST) CEO Barber sells $2400 in stock  Investing.com

Aquestive Therapeutics (AQST) CEO Barber sells $2400 in stock - Investing.com

Click here to get full coverage on $AQST stock is up 12% today. Here's what we see in our data. - Quiver Quantitative

$AQST stock is up 12% today. Here's what we see in our data.  Quiver Quantitative

$AQST stock is up 12% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Aquestive Therapeutics (AQST): A Fresh Look at Valuation After FDA Advances Sublingual Epinephrine Film - simplywall.st

Aquestive Therapeutics (AQST): A Fresh Look at Valuation After FDA Advances Sublingual Epinephrine Film  simplywall.st

Aquestive Therapeutics (AQST): A Fresh Look at Valuation After FDA Advances Sublingual Epinephrine Film - simplywall.st

Click here to get full coverage on New Analyst Forecast: $AQST Given $12.0 Price Target | AQST Stock News - Quiver Quantitative

New Analyst Forecast: $AQST Given $12.0 Price Target | AQST Stock News  Quiver Quantitative

New Analyst Forecast: $AQST Given $12.0 Price Target | AQST Stock News - Quiver Quantitative

Click here to get full coverage on Aquestive Therapeutics: Expect Its Torrid Pace To Relax (Rating Downgrade) (NASDAQ:AQST) - Seeking Alpha

Aquestive Therapeutics: Expect Its Torrid Pace To Relax (Rating Downgrade) (NASDAQ:AQST)  Seeking Alpha

Aquestive Therapeutics: Expect Its Torrid Pace To Relax (Rating Downgrade) (NASDAQ:AQST) - Seeking Alpha

Click here to get full coverage on Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year? - Yahoo Finance

Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?  Yahoo Finance

Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year? - Yahoo Finance

Click here to get full coverage on Mixed Catalysts Drive After-Hours Moves In MRM, LEXX, SHOT, AQST, And OVID - Nasdaq

Mixed Catalysts Drive After-Hours Moves In MRM, LEXX, SHOT, AQST, And OVID  Nasdaq

Mixed Catalysts Drive After-Hours Moves In MRM, LEXX, SHOT, AQST, And OVID - Nasdaq

Click here to get full coverage on Compared to Estimates, Aquestive Therapeutics (AQST) Q2 Earnings: A Look at Key Metrics - Nasdaq

Compared to Estimates, Aquestive Therapeutics (AQST) Q2 Earnings: A Look at Key Metrics  Nasdaq

Compared to Estimates, Aquestive Therapeutics (AQST) Q2 Earnings: A Look at Key Metrics - Nasdaq

Click here to get full coverage on Aquestive Therapeutics Inc (AQST) Q1 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance

Aquestive Therapeutics Inc (AQST) Q1 2025: Everything You Need To Know Ahead Of Earnings  Yahoo Finance

Aquestive Therapeutics Inc (AQST) Q1 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance

Click here to get full coverage on Aquestive Therapeutics (NASDAQ:AQST) Updates Amid Dow Jones Industrial Average - Kalkine Media

Aquestive Therapeutics (NASDAQ:AQST) Updates Amid Dow Jones Industrial Average  Kalkine Media

Aquestive Therapeutics (NASDAQ:AQST) Updates Amid Dow Jones Industrial Average - Kalkine Media

Click here to get full coverage on Aquestive Therapeutics: No AdCom For Anaphylm Derisks January Approval Catalyst (AQST) - Seeking Alpha

Aquestive Therapeutics: No AdCom For Anaphylm Derisks January Approval Catalyst (AQST)  Seeking Alpha

Aquestive Therapeutics: No AdCom For Anaphylm Derisks January Approval Catalyst (AQST) - Seeking Alpha

Click here to get full coverage on JMP Securities Maintains Aquestive Therapeutics (AQST) Market Outperform Recommendation - Nasdaq

JMP Securities Maintains Aquestive Therapeutics (AQST) Market Outperform Recommendation  Nasdaq

JMP Securities Maintains Aquestive Therapeutics (AQST) Market Outperform Recommendation - Nasdaq

Click here to get full coverage on Aquestive Therapeutics to Report Third Quarter 2025 - GlobeNewswire

Aquestive Therapeutics to Report Third Quarter 2025  GlobeNewswire

Aquestive Therapeutics to Report Third Quarter 2025 - GlobeNewswire

Click here to get full coverage on First-Ever Needle-Free Epinephrine Film: Aquestive's Anaphylm Clears Key FDA Hurdle Without Committee Review - Stock Titan

First-Ever Needle-Free Epinephrine Film: Aquestive's Anaphylm Clears Key FDA Hurdle Without Committee Review  Stock Titan

First-Ever Needle-Free Epinephrine Film: Aquestive's Anaphylm Clears Key FDA Hurdle Without Committee Review - Stock Titan

Click here to get full coverage on Oppenheimer Raises AQST Target Price, Shares Surge - StocksToTrade

Oppenheimer Raises AQST Target Price, Shares Surge  StocksToTrade

Oppenheimer Raises AQST Target Price, Shares Surge - StocksToTrade

Click here to get full coverage on New Analyst Forecast: $AQST Given 'Outperform' Rating - Quiver Quantitative

New Analyst Forecast: $AQST Given 'Outperform' Rating  Quiver Quantitative

New Analyst Forecast: $AQST Given 'Outperform' Rating - Quiver Quantitative

Click here to get full coverage on Insider Sale: Chief Operating Officer of $AQST Sells 62,180 Shares - Quiver Quantitative

Insider Sale: Chief Operating Officer of $AQST Sells 62,180 Shares  Quiver Quantitative

Insider Sale: Chief Operating Officer of $AQST Sells 62,180 Shares - Quiver Quantitative

Click here to get full coverage on EpiPen Veteran to Lead Aquestive's Revolutionary Oral Epinephrine Launch as New Chief Commercial Officer - Stock Titan

EpiPen Veteran to Lead Aquestive's Revolutionary Oral Epinephrine Launch as New Chief Commercial Officer  Stock Titan

EpiPen Veteran to Lead Aquestive's Revolutionary Oral Epinephrine Launch as New Chief Commercial Officer - Stock Titan

Click here to get full coverage on Aquestive jumps as FDA says no AdCom for allergy therapy Anaphylm - Seeking Alpha

Aquestive jumps as FDA says no AdCom for allergy therapy Anaphylm  Seeking Alpha

Aquestive jumps as FDA says no AdCom for allergy therapy Anaphylm - Seeking Alpha

Click here to get full coverage on Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share (NASDAQ:AQST) - Seeking Alpha

Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share (NASDAQ:AQST)  Seeking Alpha

Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share (NASDAQ:AQST) - Seeking Alpha

Click here to get full coverage on Jim Cramer on Aquestive Therapeutics: “I Think It’s a Very Interesting Spec” - Yahoo Finance

Jim Cramer on Aquestive Therapeutics: “I Think It’s a Very Interesting Spec”  Yahoo Finance

Jim Cramer on Aquestive Therapeutics: “I Think It’s a Very Interesting Spec” - Yahoo Finance

Click here to get full coverage on Aquestive Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat

Aquestive Therapeutics Q3 2025 Earnings Call Transcript  MarketBeat

Aquestive Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat

Click here to get full coverage on Aquestive Therapeutics Stock Surges on FDA Approval and Analyst Upgrades - StocksToTrade

Aquestive Therapeutics Stock Surges on FDA Approval and Analyst Upgrades  StocksToTrade

Aquestive Therapeutics Stock Surges on FDA Approval and Analyst Upgrades - StocksToTrade

Click here to get full coverage on Aquestive Therapeutics Stock: Significant Upside Potential (NASDAQ:AQST) - Seeking Alpha

Aquestive Therapeutics Stock: Significant Upside Potential (NASDAQ:AQST)  Seeking Alpha

Aquestive Therapeutics Stock: Significant Upside Potential (NASDAQ:AQST) - Seeking Alpha

Click here to get full coverage on A Look at Aquestive Therapeutics’s Valuation Following Positive FDA Update on Anaphylm - Yahoo Finance

A Look at Aquestive Therapeutics’s Valuation Following Positive FDA Update on Anaphylm  Yahoo Finance

A Look at Aquestive Therapeutics’s Valuation Following Positive FDA Update on Anaphylm - Yahoo Finance

Click here to get full coverage on AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA - The Globe and Mail

AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA  The Globe and Mail

AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA - The Globe and Mail

Click here to get full coverage on Aquestive therapeutics (AQST): Chief medical officer sells $141,904 in stock By Investing.com - Investing.com Australia

Aquestive therapeutics (AQST): Chief medical officer sells $141,904 in stock By Investing.com  Investing.com Australia

Aquestive therapeutics (AQST): Chief medical officer sells $141,904 in stock By Investing.com - Investing.com Australia

Click here to get full coverage on Looking at the Narrative for Aquestive Therapeutics After Patent Wins and FDA Milestones - Yahoo Finance

Looking at the Narrative for Aquestive Therapeutics After Patent Wins and FDA Milestones  Yahoo Finance

Looking at the Narrative for Aquestive Therapeutics After Patent Wins and FDA Milestones - Yahoo Finance

Click here to get full coverage on Citizens raises Aquestive Therapeutics stock price target to $12 on extended patent protection - Investing.com

Citizens raises Aquestive Therapeutics stock price target to $12 on extended patent protection  Investing.com

Citizens raises Aquestive Therapeutics stock price target to $12 on extended patent protection - Investing.com

Click here to get full coverage on Aquestive Therapeutics (NASDAQ:AQST) Advances Pharma Delivery - Kalkine Media

Aquestive Therapeutics (NASDAQ:AQST) Advances Pharma Delivery  Kalkine Media

Aquestive Therapeutics (NASDAQ:AQST) Advances Pharma Delivery - Kalkine Media

Click here to get full coverage on Oppenheimer Raises Price Target for Aquestive Therapeutics Amid FDA Developments - StocksToTrade

Oppenheimer Raises Price Target for Aquestive Therapeutics Amid FDA Developments  StocksToTrade

Oppenheimer Raises Price Target for Aquestive Therapeutics Amid FDA Developments - StocksToTrade

Click here to get full coverage on Aquestive Therapeutics SVP sells $63,000 in shares - Investing.com

Aquestive Therapeutics SVP sells $63,000 in shares  Investing.com

Aquestive Therapeutics SVP sells $63,000 in shares - Investing.com

Click here to get full coverage on Aquestive stock gains on FDA review for allergy drug (AQST) - Seeking Alpha

Aquestive stock gains on FDA review for allergy drug (AQST)  Seeking Alpha

Aquestive stock gains on FDA review for allergy drug (AQST) - Seeking Alpha

Click here to get full coverage on Aquestive Therapeutics Secures New Patents for Anaphylm™ Sublingual Film, Extending Protection Through 2037 - Quiver Quantitative

Aquestive Therapeutics Secures New Patents for Anaphylm™ Sublingual Film, Extending Protection Through 2037  Quiver Quantitative

Aquestive Therapeutics Secures New Patents for Anaphylm™ Sublingual Film, Extending Protection Through 2037 - Quiver Quantitative

Click here to get full coverage on ARS Pharma Urges FDA To Delay Approval Of Aquestive's Allergic Reaction Treatment - Sahm

ARS Pharma Urges FDA To Delay Approval Of Aquestive's Allergic Reaction Treatment  Sahm

ARS Pharma Urges FDA To Delay Approval Of Aquestive's Allergic Reaction Treatment - Sahm

Click here to get full coverage on First-Ever Oral Emergency Allergy Treatment Gets $75M Boost from RTW Investment - Stock Titan

First-Ever Oral Emergency Allergy Treatment Gets $75M Boost from RTW Investment  Stock Titan

First-Ever Oral Emergency Allergy Treatment Gets $75M Boost from RTW Investment - Stock Titan

Click here to get full coverage on Revolutionary Needle-Free Epinephrine Treatment Advances: FDA Sets 2026 Decision Date for Oral Anaphylaxis Drug - Stock Titan

Revolutionary Needle-Free Epinephrine Treatment Advances: FDA Sets 2026 Decision Date for Oral Anaphylaxis Drug  Stock Titan

Revolutionary Needle-Free Epinephrine Treatment Advances: FDA Sets 2026 Decision Date for Oral Anaphylaxis Drug - Stock Titan

Click here to get full coverage on Sublingual epinephrine outcomes fall between manual injection, autoinjectors - Healio

Sublingual epinephrine outcomes fall between manual injection, autoinjectors  Healio

Sublingual epinephrine outcomes fall between manual injection, autoinjectors - Healio

Click here to get full coverage on Aquestive Therapeutics: Updating The Anaphylm Timeline To Approval (NASDAQ:AQST) - Seeking Alpha

Aquestive Therapeutics: Updating The Anaphylm Timeline To Approval (NASDAQ:AQST)  Seeking Alpha

Aquestive Therapeutics: Updating The Anaphylm Timeline To Approval (NASDAQ:AQST) - Seeking Alpha

Click here to get full coverage on AQST: Aquestive Therapeutics Showcases Anaphylm Film at Allergy Summit | AQST Stock News - GuruFocus

AQST: Aquestive Therapeutics Showcases Anaphylm Film at Allergy Summit | AQST Stock News  GuruFocus

AQST: Aquestive Therapeutics Showcases Anaphylm Film at Allergy Summit | AQST Stock News - GuruFocus

Click here to get full coverage on Aquestive Therapeutics Stock Is Rising Pre-Market – Its $75M Funding Agreement Draws Divided Opinions From Retail - Stocktwits

Aquestive Therapeutics Stock Is Rising Pre-Market – Its $75M Funding Agreement Draws Divided Opinions From Retail  Stocktwits

Aquestive Therapeutics Stock Is Rising Pre-Market – Its $75M Funding Agreement Draws Divided Opinions From Retail - Stocktwits

Click here to get full coverage on Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting - Yahoo Finance

Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting  Yahoo Finance

Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting - Yahoo Finance

Click here to get full coverage on Watching the Narrative for Aquestive Therapeutics Shift After Key Anaphylm Milestones - Yahoo Finance

Watching the Narrative for Aquestive Therapeutics Shift After Key Anaphylm Milestones  Yahoo Finance

AQST

Price Chart

Key Statistics

Technicals

About AQST

Latest News

Piper Sandler Maintains Aquestive Therapeutics (AQST) Overweight Recommendation - Nasdaq

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.10 - Yahoo Finance

Is Aquestive Therapeutics Stock Built to Withstand a Pullback? - Trefis

Advanced Charts

Top Gainers

Top Losers